EW - Edwards Lifesciences Corp logo

EW

Edwards Lifesciences Corp

Compare EW Hold

Edwards Lifesciences provides medical products and technologies for advanced cardiovascular diseases, focusing on transcatheter heart valve replacements and repairs, along with surgical solutions for aortic and mitral valve conditions.

⚕️ Healthcare NYSE Listed 2000 $ USD
$1,000 invested 20 years ago →$22,283today

Score Overview

1 Year
Score
Net Growth-6.39%
Net TrendShrank
Net Income Consistency—
Rev Growth7.33%
Rev TrendGrew
Revenue Consistency—
5 Years
Score5.1
Net Growth-33.14%
Net Trend40%
Net Income Consistency—
Rev Growth24.46%
Rev Trend80%
Revenue Consistency—
10 Years
Score
Net Growth76.45%
Net Trend60%
Net Income Consistency
Rev Growth119.74%
Rev Trend90%
Revenue Consistency
20 Years
Score8.0
Net Growth7x
Net Trend65%
Net Income Consistency
Rev Growth6x
Rev Trend95%
Revenue Consistency
All Time
Score
Net Growth469.45%
Net Trend69%
Net Income Consistency
Rev Growth8x
Rev Trend92%
Revenue Consistency

Explore the 2021 public Archive ranking →

Where Edwards Lifesciences Corp has ranked, year by year

Measure
Fundamentals Window
1Y5Y10Y20Y30YAll time

Showing 10 years ranking history by HDB Score.

Reached the top 50 on HDB Score in 1 year, the longest run being 1 in a row — but not in 2021.

  • EW

2011: 29.5% · 2021: 5.2% · free through 2021 · longest runs

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-09-28
$ 86.83—
1 Year2025-09-26
$ 76.2513.88%
5 Years2021-09-28
$ 113.86-23.74%
10 Years2016-09-28
$ 40.15116.25%
20 Years2006-09-28
$ 3.9022x
All Time2000-03-27
$ 1.3863x

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2026$ 6.51B$ 1.00B
2025$ 6.06B$ 1.07B$ 4.22B
2024$ 5.43B$ 4.17B$ 3.97B
2023$ 6.00B$ 1.40B$ 1.63B
2022$ 5.38B$ 1.52B$ 1.21B
2021$ 5.23B$ 1.50B$ 1.46B
2020$ 4.38B$ 823M$ 1.40B
2019$ 4.34B$ 1.04B$ 1.51B
2018$ 3.72B$ 722M$ 956M
2017$ 3.43B$ 622M$ 1.33B
2016$ 2.96B$ 569M$ 1.27B
2015$ 2.49B$ 494M$ 1.22B
2014$ 2.32B$ 811M$ 1.43B
2013$ 2.04B$ 391M$ 936M
2012$ 1.89B$ 293M$ 521M
2011$ 1.67B$ 236M$ 450M
2010$ 1.44B$ 218M$ 396M
2009$ 1.32B$ 229M$ 334M
2008$ 1.23B$ 128M$ 226M
2007$ 1.09B$ 113M$ 191M
2006$ 1.03B$ 130M$ 182M
2005$ 997M$ 79M$ 178M
2004$ 931M$ 1M$ 48M
2003$ 860M$ 79M$ 61M
2002$ 704M$ 55M$ 34M
2001$ 692M-$ 12M$ 48M
IPO2000$ 804M-$ 272M$ 28M
EW - Edwards Lifesciences Corp logo

Edwards Lifesciences Corp fundamental performance

Between 2015 and 2025, revenue grew from $ 2.49B to $ 6.06B and net income grew from $ 494M to $ 1.07B. Revenue increased in 9 of those 10 years; net income in 6.

Between 2005 and 2025, revenue grew from $ 997M to $ 6.06B and net income grew from $ 79M to $ 1.07B. Revenue increased in 19 of those 20 years; net income in 13.

Edwards Lifesciences Corp currently holds a 20-year HDB Score of 8.0 out of 10. How the HDB Score is calculated.

Membership

Continue EW’s history

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 3,816 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year · Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies